Pass the ACRP Certified Professional ACRP-CP Questions and answers with ExamsMirror

The PI is responsible for ensuring accurate documentation of adverse events (AEs) in the medical chart, including their relationship to the investigational product (IP). If an omission is identified, the PI must correct it by making a dated and signed amendment to maintain data accuracy and completeness.

GCP guidelines state that the PI must maintain accurate and complete records, including the assessment of the relationship between AEs and the IP.

"The investigator must document the assessment of the relationship between the AE and the investigational product to ensure accurate clinical records."

Objectives:

Maintain accuracy in adverse event documentation.

Ensure data integrity through appropriate corrections.

The sponsor is responsible for ensuring that agreements are in place with all involved parties (including investigators and institutions) to grant direct access to trial-related source documents. This is crucial for monitoring, auditing, and inspection purposes, ensuring transparency and compliance with regulatory requirements.

According to GCP guidelines, the sponsor must establish agreements to secure direct access to trial data for verification and compliance checks.

"The sponsor should ensure that agreements are in place to permit direct access to source data and documents for monitoring and inspection."

Objectives:

Maintain compliance with regulatory requirements.

Facilitate data verification and quality assurance.

The Principal Investigator (PI) is ultimately responsible for maintaining and documenting any unblinding events related to the investigational product (IP). This accountability ensures that any instance where the blind is broken is properly justified, documented, and reported to maintain trial integrity.

GCP guidelines state that the PI must oversee the unblinding process and ensure proper documentation to protect the validity of the trial data.

"The PI is responsible for ensuring that any unblinding of the investigational product is adequately documented and reported according to protocol."

Objectives:

Maintain the integrity of blinded studies.

Properly document unblinding incidents.

Monitors are responsible for reviewing documents that pertain to study conduct and data integrity,including regulatory binders, informed consent forms (ICFs), and documentation of study drug administration. However, reviewing potential patient medical records for eligibility prior to the informed consent process is not part of a monitor's responsibilities, as this would violate patient confidentiality and GCP standards.

According to GCP guidelines, monitors should ensure compliance with the protocol and data integrity but should not access non-consented patient records.

"Monitors should verify that only enrolled and consented subjects' data are reviewed, ensuring compliance with privacy regulations."

Objectives:

Understand the scope of monitoring responsibilities.

Protect patient confidentiality during the monitoring process.

The Principal Investigator (PI) is responsible for conducting a root cause analysis when non-compliance is identified at the site. The PI must identify the reasons for non-compliance and develop a Corrective and Preventive Action (CAPA) plan to address and prevent future occurrences.

This answer aligns with GCP principles that designate the PI as responsible for site-level compliance and corrective actions.

"The PI must take responsibility for investigating the cause of non-compliance and developing a CAPA plan to mitigate recurrence."

Objectives:

Maintaining compliance and data integrity

Addressing non-compliance proactively

When the IRB/IEC decides not to approve a clinical trial, they must notify the Principal Investigator (PI) in writing. This communication ensures that the PI is formally informed of the decision and cantake appropriate actions, such as revising the protocol or addressing the reasons for disapproval.

According to GCP guidelines, the IRB/IEC must communicate any decision regarding the approval status of a study directly to the PI, as the PI is responsible for the conduct of the trial.

"The IRB/IEC should promptly notify the investigator in writing of its decision to approve or disapprove the proposed research activity."

Objectives:

Maintain clear communication between the IRB/IEC and the investigator.

Ensure timely notification of decisions affecting the study.

When a study is temporarily suspended, the primary responsibility of the research team is to ensure the ongoing care and safety of the enrolled participants. Participants must be informed about the suspension and assured that their health and safety will continue to be monitored.

GCP guidelines prioritize the safety and well-being of participants, which must be maintained even during a temporary suspension.

"In the event of a study suspension, the first priority is to inform the participants and ensure that appropriate care and monitoring are continued."

Objectives:

Protect participant safety during study suspension.

Maintain clear communication with study participants.

The IRB/IEC is responsible for reviewing and approving the consent form, which must include any information about payments to participants. This ensures transparency and ethical compliance regarding compensation.

The answer is verified according to GCP guidelines, which mandate IRB/IEC review of consentforms, including payment details.

"IRB/IEC must ensure that the informed consent process is thorough and includes disclosure of any compensation or payment to participants."

Objectives:

Guaranteeing informed consent quality

Ensuring transparency about participant payments

Lab reports contain individual participant data relevant to their health status and the study's outcomes. These reports are essential for verifying subject safety and evaluating the effects of the investigational product (IP). Therefore, they must be retained in the participant’s medical records.

According to GCP guidelines, participant charts must include laboratory data as part of the essential documents to ensure accurate and complete clinical records.

"Lab reports must be maintained as part of the participant’s chart for safety monitoring and data verification."

Objectives:

Maintain comprehensive medical records for each participant.

Ensure availability of clinical data for audit and review.

All financial agreements, including compensation, budgeting, and payment terms related to the conduct of a clinical trial, are documented in the signed contract between the sponsor and the site. This contract outlines the financial responsibilities and ensures transparency and compliance.

GCP guidelines stipulate that financial matters related to the conduct of a trial are to be formally documented in contractual agreements.

"The financial aspects of a clinical trial must be outlined in the signed agreement between the sponsor and the site, ensuring clear understanding of compensation and obligations."

Objectives:

Ensure financial transparency and accountability.

Maintain compliance with contractual obligations.